SCHEDULE: Vivo Capital Reduces Instil Bio Stake to 4.5%

Vivo Capital entities have reported a 4.5% passive ownership stake in Instil Bio, Inc., holding 292,743 shares of common stock.

Summary

• Vivo Capital IX, LLC and Vivo Capital Fund IX, L.P. are the reporting persons for this beneficial ownership statement.
• They collectively beneficially own 292,743 shares of Instil Bio, Inc. common stock.
• This ownership represents 4.5% of Instil Bio's total outstanding common stock.
• The percentage calculation is based on 6,559,927 shares of common stock issued and outstanding as of May 9, 2025, as disclosed in Instil Bio's Quarterly Report on Form 10-Q.
• The event date requiring this amendment was June 30, 2025.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in Vivo Capital's beneficial ownership to 4.5%, suggesting a partial divestment from a previously higher stake, which can be interpreted as a slight negative signal for the company.

Positives

• Vivo Capital, a recognized investment firm, maintains a significant, albeit passive, stake in Instil Bio, Inc.

Negatives

• Vivo Capital's ownership stake in Instil Bio has decreased to 4.5%, indicating a reduction from a previously higher beneficial ownership that triggered the initial Schedule 13G filing.

Risks

• The reporting persons are passive investors and have certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Instil Bio.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Instil Bio's future outlook.

Industry Context

This filing is a routine disclosure of an institutional investor's stake and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May view the reduction in Vivo Capital's stake as a slight negative signal regarding the company's prospects, potentially influencing investor sentiment.

Key Dates

Recommendation

This Schedule 13G filing indicates a reduction in Vivo Capital's beneficial ownership of Instil Bio to 4.5%, falling below the 5% threshold that typically triggers such filings. While the filing itself is a routine disclosure, the decrease in a notable institutional investor's stake could be interpreted as a slight negative signal, suggesting a re-evaluation of the investment. However, without further financial or operational updates from Instil Bio, this information alone is insufficient to warrant a strong buy or sell recommendation. Investors should monitor future filings and company performance for a more comprehensive assessment.

Keywords

Instil Bio, Vivo Capital, beneficial ownership, Schedule 13G, common stock, passive investment, biotechnology